Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: Inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement

Annals of Oncology

Volumn 13, Issue 8, 2002, Pages 1290-1299

  Visco, C ^a   Medeiros, L J ^a   Jones, D ^a   Smith, T ^a   Rodriguez, M A ^a   McLaughlin, P ^a   Romaguera, J ^a   Cabanillas, F ^a   Sarris, A H ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Histology; Lymphoma; Prognosis; Skin; Stage

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; LACTATE DEHYDROGENASE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SKIN LYMPHOMA; T CELL LYMPHOMA; TREATMENT FAILURE; TUMOR LOCALIZATION; DISEASE FREE SURVIVAL; ENZYMOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTIOCYTIC LYMPHOMA; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; PATHOLOGY; PERIPHERAL T CELL LYMPHOMA; REMISSION; SKIN TUMOR; SURVIVAL RATE; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPHENOTYPING; LACTATE DEHYDROGENASE; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE-CELL; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL RATE; T-LYMPHOCYTES; TREATMENT OUTCOME; HUMANS; L-LACTATE DEHYDROGENASE; MIDDLE AGED;

EID: 0036668671     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf206     Document Type: Article

References (53)

1. Extranodal lymphomas
2. Cutaneous malignant lymphoma
3. EORTC classification for primary cutaneous lymphomas: A comparison with the REAL classification and the proposed WHO classification
4. Cutaneous B-cell lymphoma
5. Primary cutaneous B-cell lymphoma: Review and current concepts
6. EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer
7. Primary B-cell lymphomas of the skin
8. Primary cutaneous B-cell lymphoma: A unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83 cases
9. Primary cutaneous T-cell lymphoma: Review and current concepts
10. Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: A clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy
11. Cutaneous lymphomas other than mycosis fungoides: Follow-up study of 52 patients
12. Combined modality therapy with electron-beam irradiation and systemic chemotherapy for cutaneous T-cell lymphomas
13. Treatment of multi-focal primary cutaneous B-cell lymphoma: A clinical follow-up study of 29 patients
14. Primary cutaneous large-cell lymphoma: Analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte
15. Radiotherapy in the management of cutaneous B-cell lymphoma. Our experience in 25 cases
16. Radiotherapy of cutaneous B-cell lymphomas
17. Reticulohistiocytoma of the dorsum
18. Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor Stage I: Preferential cutaneous relapses but high cure rate with doxorubicin-based therapy
19. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997
20. Lymphomatoid papulosis: A T-cell dyscrasia with a propensity to transform into malignant lymphoma
21. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'
22. Report of the Committee on Hodgkin's Disease Staging Classification
23. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage
24. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
25. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma
26. A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma
27. Successful outcome of patients with good risk large cell lymphoma (LCL) with a shortened schedule of treatment (RX)
28. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy
29. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
30. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin-vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis
31. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma
32. Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma
33. Nonparametric estimation from incomplete observations
34. Regression models and life tables
35. Primary cutaneous CD30-positive large cell lymphoma: Definition of a new type of cutaneous lymphoma with a favorable prognosis. A European Multicenter Study of 47 patients
36. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives)
37. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma
38. Cutaneous follicular lymphoma
39. Primary cutaneous follicular centre-cell lymphoma-a lymphoproliferative disease with favourable prognosis
40. Mycosis fungoides: Disease evolution and prognosis of 309 Dutch patients
41. Characterization of T-cell subpopulations in skin and peripheral blood of patients with cutaneous T-cell lymphomas and benign inflammatory dermatoses
42. Phenotypic characterization of skin-infiltrating T cells in cutaneous T-cell lymphoma: Comparison with benign cutaneous T-cell infiltrates
43. Abnormalities of circulating T-cell subpopulations in patients with cutaneous T-cell lymphoma: Cutaneous lymphocyte-associated antigen expression on T cells correlates with extent of disease
44. Differential expression of the HECA-452 antigen (cutaneous lymphocyte associated antigen, CLA) in cutaneous and non-cutaneous T-cell lymphomas
45. T-cell population of primary and secondary cutaneous B-cell lymphomas does not express the cutaneous lymphocyte-associated antigen (CLA)
46. Characterization of E-selectin-binding epitopes expressed by skin-homing T cells
47. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
48. Cytokine loops involving interferon-γ and IP-10, a cytokine chemotactic for CD4+ lymphocytes: An explanation for the epidermotropism of cutaneous T-cell lymphoma?
49. Tumor necrosis factor-α and interferon-γ, but not HTLV-I tax, are likely factors in the epidermotropism of cutaneous T-cell lymphoma via induction of interferon-inducible protein-10
50. Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues and human peripheral blood lymphocytes-SCID mice
51. The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides
52. Human recombinant interferon-inducible protein-10 inhibits the proliferation of normal and acute myelogenous leukemia progenitors
53. Primary cutaneous T-cell lymphoma: Clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma